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Abstract 
Background: The World Health Organization (WHO) recommends combinations of an artemisinin derivative plus 
an anti‑malarial drug of longer half‑life as treatment options for uncomplicated Plasmodium falciparum infections. In 
Africa, artesunate–mefloquine (ASMQ) is an infrequently used artemisinin‑based combination therapy (ACT) because 
of perceived poor tolerance to mefloquine. However, the WHO has recommended reconsideration of the use of 
ASMQ in Africa. In this large clinical study, the pharmacokinetics (PK) of a fixed dose combination of ASMQ was inves‑
tigated in an African paediatric population to support dosing recommendations used in Southeast Asia and South 
America.
Methods: Among the 472 paediatric patients aged 6–59 months from six African centres included in the large 
clinical trial, a subset of 50 Kenyan children underwent intensive sampling to develop AS, its metabolite dihydroarte‑
misinin (DHA) and MQ PK models. The final MQ PK model was validated using sparse data collected in the remaining 
participants  (NONMEM®). The doses were one or two tablets containing 25/55 mg AS/MQ administered once a day 
for 3 days according to patients’ age. A sensitive LC–MS/MS method was used to quantify AS, DHA and MQ concen‑
trations in plasma. An attempt was made to investigate the relationship between the absence/presence of malaria 
recrudescence and MQ area under the curve (AUC) using logistic regression.
Results: AS/DHA concentration–time profiles were best described using a one‑compartment model for both 
compounds with irreversible AS conversion into DHA. AS/DHA PK were characterized by a significant degree of vari‑
ability. Body weight affected DHA PK parameters. MQ PK was characterized by a two‑compartment model and a large 
degree of variability. Allometric scaling of MQ clearances and volumes of distribution was used to depict the relation‑
ship between MQ PK and body weight. No association was found between the model predicted AUC and appearance 
of recrudescence.
Conclusions: The population pharmacokinetic models developed for both AS/DHA and MQ showed a large vari‑
ability in drug exposure in the investigated African paediatric population. The largest contributor to this variability 
was body weight, which is accommodated for by the ASMQ fixed dose combination (FDC) dosing recommendation. 
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Background
The World Health Organization (WHO) estimates a sig-
nificant 18% reduction in the incidence of malaria along 
with a considerable 28% decrease in the malaria mortality 
rate between 2010 and 2017 [1]. Despite this substantial 
progress, the disease still caused an estimated 435,000 
deaths worldwide, mostly in Africa (93%) and in children 
under 5 years of age (61%) [1]. Artemisinin-based com-
bination therapy (ACT) is the first-line treatment for 
uncomplicated Plasmodium falciparum infection, the 
predominant cause of malaria in Africa, recommended 
by the WHO since 2001 [2]. These combinations involve 
a rapidly eliminated and fast-acting artemisinin deriva-
tive together with a much more slowly eliminated drug 
that kills the remaining parasites. One of the five WHO 
recommended artemisinin-based combinations is artesu-
nate (AS) associated with mefloquine (MQ), extensively 
used in Asia and Latin America for the last 20 years [3]. 
This combination is less commonly selected in Africa, 
because of the availability of other affordable and already 
registered artemisinin-based combinations [4], as well as 
existing concerns about MQ tolerability [5, 6]. However, 
the WHO has recommended reconsideration of the use 
of ASMQ in Africa in order to increase the number of 
artemisinin-based combinations available, with the con-
sequent reduction of the risk of developing drug resist-
ance [4].
The development of a fixed-dose combination (FDC) 
of AS and MQ was begun in 2002 by the Drugs for 
Neglected Diseases initiative (DNDi) with the fixed-dose 
artesunate-based combination therapy (FACT) Consor-
tium [3]. This combination has been demonstrated to 
be efficacious and safe in Asia and Latin America [7–9], 
but there is still limited experience with its use in Africa. 
Therefore, an open-label, prospective, randomized, con-
trolled, multi-centre, non-inferiority clinical trial evalu-
ating the efficacy, safety and pharmacokinetics of the 
ASMQ FDC versus artemether–lumefantrine (AMLF) 
in children aged 6–59  months was conducted in Africa 
by DNDi (Pan African Clinical Trials Registry number 
PACTR201202000278282). Because MQ dose splitting 
into three equal daily doses has been shown to optimize 
treatment compliance and to improve MQ tolerability 
[10, 11], FDC ASMQ dispersible tablets were adminis-
tered over three consecutive days based on the patients’ 
age. The efficacy of ASMQ was found to be non-inferior 
to the efficacy of AMLF and the safety of the two treat-
ments was found to be similar with low risk of repeated 
early vomiting, indicating that ASMQ is a valuable treat-
ment option for children younger than 5  years with 
uncomplicated falciparum malaria in Africa [12]. Within 
the framework of this previous study, a pharmacokinetic 
study was conducted to characterize ASMQ FDC phar-
macokinetics in the African paediatric patient popula-
tion, to compare it to data gathered in adult patients 
and volunteers, to validate the recommended treatment 
regimen, and to explore the relationships between drug 
exposure and treatment outcomes.
Methods
Study design and participants
The clinical trial was carried out in six African cen-
tres: three in Tanzania, two in Burkina Faso and one in 
Kenya. Written informed consent from a parent/guard-
ian was required to enrol children younger than 5 years 
in the trial, who were infected by P. falciparum, as con-
firmed by microscopy (density between 2000 and 200,000 
asexual parasites/µL), and with fever equal to or higher 
than 37.5  °C. Exclusion criteria were children with 
body weight less than 5  kg, signs of severe/complicated 
malaria, febrile conditions caused by diseases other than 
malaria, a known hypersensitivity to the study drugs, a 
mixed plasmodium infection, a history of anti-malarial 
treatment in the 2 weeks preceding the trial or 4 weeks in 
case of mefloquine and piperaquine, prior participation 
in a therapeutic trial within 3 months or inability to toler-
ate oral medication. Patients were followed up to day 63 
after start of treatment or to the first recurrence of infec-
tion. The study protocol was reviewed and approved by 
national and independent ethics committees of all par-
ticipating centres.
Of the 945 patients enrolled in the trial, 473 were rand-
omized to the ASMQ arm (one of them was never dosed) 
and 472 were randomized to the AMLF arm. The phar-
macokinetic analysis described here was performed on 
the 472 patients who received ASMQ.
Administered doses for these patients were one or two 
dispersible tablets containing 25 mg AS and 55 mg MQ 
once a day for three consecutive days to children aged 
from 6 to 11 months and from 12 to 59 months, respec-
tively. Clinical and parasitological examinations were 
scheduled at baseline, i.e. before drug administration, at 
Besides body weight considerations, there is no indication that the dosage should be modified in children with 
malaria compared to adults.
Trial registration Pan African Clinical Trials Registry PACTR201202000278282 registration date 2011/02/16
Keywords: Population pharmacokinetics, Mefloquine, Artesunate, Dihydroartemisinin
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day 0 (D0), D1, D2, D3, D7, D14, D21, D28, D35, D42, 
D49, D56 and D63 and on any other day if the patient 
spontaneously returned and parasitological reassessment 
was required (as per protocol). A margin of ± 2  days to 
the assigned day of visit was allowed from D7 onward. In 
case of recurrence of parasitaemia on D7, D14, D21, D28, 
D35, D42, D49, and D56 the date was recorded and the 
type of recurrence was determined by PCR (appearance 
of new infection, malaria recrudescence, missing PCR 
information or undetermined type).
According to the study protocol, the first fifty children 
from Kenya enrolled in the ASMQ arm underwent inten-
sive blood sampling: at baseline, on D0 after drug admin-
istration (until 6 h after first dosing), D2 (until 6 h after 
the third dose), D3 (72 h after first dose), D7 and on one 
other occasion on day 28, 35, 42, 49, 56 or 63. Two blood 
samples, at baseline and on D7, were collected for all 
the other participants. Additionally, for all patients with 
recurrence of parasitaemia, a blood sample was taken on 
the day of failure.
Analytical methods
The mass spectrometry assay for AS, DHA and MQ 
used for the analysis of study samples is an adaptation 
of a previously published validated multiplex method 
[13]. The assay has been further improved by the use of 
stable isotopically labelled internal standards for MQ 
(mefloquine-d9) and DHA (DHA-13Cd4) to circumvent 
the potential matrix effect that may affect the accuracy of 
mass detection.
The mobile phase was delivered at a flow rate of 
0.3 mL/min on a 2.1 mm × 75 mm XSelect HSS 3.5 μm 
column (Waters, Milford, MA, USA), using solvent A 
(2  mM ammonium acetate + 0.1% FA) and solvent B 
(MeCN + 0.1% FA) distributed according to the following 
stepwise gradient program: 98% A: 0 min; 98% A → 15% 
A: from 0.0  min → 13.0  min followed by a re-equilibra-
tion step to the initial solvent proportions. The retention 
time of mefloquine/mefloquine-d9, DHA/DHA-13Cd4 
and artesunate is 7.4  min, 8.2  min and 9.2  min, respec-
tively. The chromatographic system was coupled to a 
triple stage quadrupole (TSQ) Quantum Ion mass spec-
trometer (MS) from Thermo Fischer Scientific (Waltham, 
MA, USA) equipped with an Ion Max electrospray ioni-
zation (ESI) interface. The limits of quantification (LOQ) 
of the method are 2.5 ng/mL for MQ and 2 ng/mL for AS 
and DHA.
Plasma samples were isolated by centrifugation and 
stored at − 20  °C until batch analysis. Briefly, 100 μL of 
plasma sample were mixed with 50 µL internal standard 
(DHA-13Cd4 at 130 ng/mL; mefloquine-d9 at 43 ng/mL) 
and extracted with 600 µL of acetonitrile. The superna-
tant (700 µL) was evaporated under nitrogen at room 
temperature and was reconstituted in 150 µL of MeOH/
ammonium acetate 2 mM (1:1) adjusted with formic acid 
at 0.1%, vortex-mixed and centrifuged again. The samples 
were maintained at +5 °C in autosampler racks through-
out the analytical series. The injection volume was 20 μL.
The method is precise (with mean inter-day 
CV  % < 10%), and accurate (inter-day deviation from 
nominal values < 5%). Since its initiation, the laboratory 
has participated in the Pharmacology Proficiency Testing 
Programme for anti-malarial drugs (http://www.wwarn 
.org/toolk it/qaqc) organized by the World Wide Antima-
larial Resistance Network WWARN (http://www.wwarn 
.org/).
Pharmacokinetics analysis
Non-linear mixed effects modelling program 
 (NONMEM®, version 7.3) [14] with the Perl-Speaks 
 NONMEM® (PsN) toolkit (version 3.7.6) [15] was used 
to estimate average population pharmacokinetic param-
eters and their associated between-subject variability 
(BSV) and to identify factors that influence them. MQ 
and AS/DHA pharmacokinetic models were developed 
on the data collected from 50 Kenyan patient subjects 
with extensive sampling. Molar units were used for AS/
DHA pharmacokinetic analyses. Because of the very fast 
rate of AS and DHA elimination and the selection of the 
trial sampling times, an external model validation could 
only be performed for MQ on the clinical trial data not 
used for model-building. Graphical exploration and sta-
tistical analyses were performed by means of the R pack-
age (version 2.15.1, R Development Core Team, http://
www.r-proje ct.org/).
Structural and statistical model
A stepwise modelling approach was undertaken to iden-
tify models that best described the MQ and AS/DHA 
pharmacokinetics. Multi-compartment dispositions with 
first-order absorption and elimination processes were 
compared for MQ. Due to the restricted amount of AS 
and DHA data, drug and metabolite pharmacokinetics 
were modelled simultaneously and directly described by 
means of a one compartment model with linear absorp-
tion and elimination. Moreover, since AS is rapidly and 
almost completely hydrolysed in DHA, its elimination 
was assumed to occur exclusively via irreversible conver-
sion to DHA [16, 17]. An adequate AS absorption rate 
constant  (Ka) estimation could not be made because of 
the small number of samples collected right after dose 
intake (one sample at maximum for each enrolled child 
on the first and third treatment day).  Ka was thus fixed 
to 3.2  h−1, the mean of previously published estimates 
retrieved from papers using a first-order process to 
depict AS absorption [17, 18].
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Parameterization was performed in terms of clearances 
(CL for drugs and  CLM for metabolite), inter-compartmen-
tal clearance (Q), central  (VC for drugs and  VM for metab-
olite) and peripheral  (VP) volumes of distribution and  Ka. 
The metabolic conversion rate from AS to DHA was esti-
mated by CL/Vc as previously discussed. AS and MQ rela-
tive bioavailability (F1, fixed to 100% and with estimated 
BSV) were also tested for AS/DHA and MQ to account 
for dose variation with respect to the nominal value due to 
the administration of water dispersible tablets. Since the 
ASMQ combination is administered orally, the pharma-
cokinetic parameter estimates represent apparent values.
Exponential errors were assumed to capture BSV in all 
the pharmacokinetic parameters. Proportional, additive 
and combined proportional-additive error models were 
compared to describe drugs and metabolite intra-patient 
(residual) variability. Finally, the correlation between AS 
and DHA concentration measurements was tested using 
the L2 function in  NONMEM®.
Covariate analysis
Available covariates were: body weight (BW), height/
length, age, sex, creatinine, total bilirubin (BIL), aspartate 
(AST) and alanine (ALT) aminotransferases, haemoglobin 
(Hb), haematocrit (Ht), total parasitaemia and co-medica-
tions categorized as CYP3A4 inducers. Visual inspection 
of the correlation between post hoc individual estimates of 
the pharmacokinetic parameters and the available patients’ 
characteristics was initially conducted to identify poten-
tial physiologically plausible relationships. Creatinine 
clearance was not evaluated since MQ elimination occurs 
mainly through non-renal processes and AS is completely 
converted into DHA, which is eliminated via glucuronida-
tion [16]. A stepwise forward insertion/backward deletion 
approach was then undertaken. Potential covariates influ-
encing the kinetic parameters were first incorporated one 
at a time and tested for significance (univariate analysis). 
Sequential multivariate combinations of the identified fac-
tors were investigated to discard redundancies and to build 
an intermediate model with all the most important covari-
ates (multivariate analysis). Finally, backward deletion 
consisted of removing covariates one at a time from the 
intermediate model, starting from the most insignificant 
until no further deterioration of the model was observed.
The influence of body weight on all MQ and DHA phar-
macokinetic parameters (PAR) was tested using allometric 
scaling:
with θ PAR population estimate, MBW the median pop-
ulation body weight and PWR the function power fixed 
(1)PAR = θ ∗
(
BW
MBW
)PWR
to 0.75 for clearances and 1 for volumes of distribution 
[19]. A linear relationship between the typical value of a 
parameter and all the other covariates (continuous cen-
tered on the population median; dichotomous coded as 
0 and 1) was used. Additionally, AST, ALT and BIL were 
implemented in the model as dichotomous variables, by 
introducing a boundary condition, i.e. below or exceed-
ing 1.5 times the upper limit of normal (ULN). Children’s 
age was used to investigate the impact of organ matura-
tion on MQ and DHA clearances, using the following 
equations, in addition to the simple linear one:
where Hill is the sigmoid power,  TM50 the AGE at 50% 
of maturation,  MATmag, the maturation magnitude for 
age, and  Kmat the age maturation rate constant [20, 21]. 
The population median covariate value was assigned to 
patients with missing information.
The acute phase of malaria is associated with altered 
gastrointestinal motility and an increased likelihood of 
vomiting. In the three-daily dose ASMQ regimen, the 
second dose is administered when the patient is in an 
improved state of health, thanks to the first dose of 
AS, that kills most of the parasites [22]. The potential 
impact of parasitaemia on AS and MQ F1 was studied 
using a linear model of log-transformed (base 10) para-
site counts measured at baseline of each ASMQ admin-
istration day. Missing parasitaemia information was 
imputed at the median value of the specific study day. 
Treatment day (0 vs. 1 and 2), considered as a surro-
gate marker of the rapid improvement in health due to 
the first AS dose, was also evaluated on AS and MQ F1. 
Since parasite counts and treatment day are correlated, 
differences in individual day 0 F1 due to parasitaemia at 
enrolment were explored, i.e. baseline parasite counts 
recorded at the first treatment day, by combining these 
two covariates. Furthermore, it was hypothesized that a 
patient’s clinical condition affects MQ  Ka and this was 
tested by integrating the effect of the treatment day (0 
vs. 1 and 2) on  Ka.
Terminal half-lives  (t1/2), maximum concentration 
 (Cmax), and time to achieve  Cmax  (tmax) for all the three 
drugs, MQ area under the curve to infinite (AUC 0–inf) 
and AS and DHA AUC 0–24 after the first and the third 
ASMQ intake were computed using final pharmacoki-
netic parameter estimates and classic pharmacokinetic 
equations or NONMEM integration, as appropriate.
(2)CL = θ ∗
1
1+
(
AGE
TM50
)
−Hill
(3)
CL = θ ∗
(
MATmag +
(
1−MATmag
)
∗
(
1− e−AGE∗Kmat
))
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Parameter estimation, model selection and exclusion 
criteria
MQ and AS/DHA concentrations were fitted using the 
first-order conditional (FOCE) method with interac-
tion. AS and DHA non-zero concentrations measured 
more than a week after last drug intake were thought 
unreliable and thus omitted from the analysis. Other 
missing variables (unreported concentration meas-
urements, dose intake or sampling times, inconsist-
ent date/time of dose intake and sampling) were also 
omitted. Data below the quantification limit (BQL) of 
the assays were handled by setting the first of a series 
of BQL samples at LOQ/2 and as missing all the others 
(M6 method) [23].
Diagnostic goodness-of-fit plots, along with dif-
ferences in the  NONMEM® objective function value 
(ΔOFV), were employed to discriminate between nested 
models. Since a ΔOFV between any two hierarchi-
cal models approximates a χ2 distribution, a change of 
more than 3.84 (p < 0.05) and 6.63 (p < 0.01) points was 
considered statistically significant for one additional 
parameter in model-building or forward insertion and 
backward-deletion covariate steps, respectively. Akaike’s 
information criterion (AIC) was used for non-hierar-
chical models. Shrinkage was also evaluated. Sensitivity 
analyses removing outlying data with absolute condi-
tional weighted residuals (CWRES) greater than 4 or 
potentially unreliable covariate values and concentra-
tion measurements were finally performed to avoid any 
potential bias in parameter estimation and covariate 
exploration.
Model validation and assessment
The stability of the final MQ and AS/DHA mod-
els was assessed by means of the bootstrap method 
implemented in PsN-Toolkit [15]. Median parameter 
values with their 95% confidence interval  (CI95%) were 
derived from 2000 replicates of the initial datasets 
and compared with the original estimates. Predic-
tion-corrected visual predictive checks (pcVPC) were 
also performed using the PsN-Toolkit and the R pack-
age Xpose4 by simulations based on the final pharma-
cokinetic models with variability using 1000 children 
[15, 24]. Moreover, the final MQ pharmacokinetic 
model was validated using concentrations collected 
from participants not used in initial model develop-
ment. The accuracy and precision of the model were 
estimated by means of prediction error (MPE) and 
root mean square error (RMSE), using log-trans-
formed concentrations, for the entire dataset and also 
for each study site [25].
Comparison between mefloquine exposures in children 
and adult volunteers and patients
Median and 90% prediction interval  (PI90  %) of children 
and adult concentration–time profiles were obtained 
through simulations (n = 1000) using the final pharma-
cokinetic model described above and published MQ phar-
macokinetic models including BSV and intra-individual 
variability, respectively. A literature search allowed the 
identification of two pharmacokinetic models developed 
in adults receiving the same fixed dose formulation of 
ASMQ as the one administered to the children enrolled 
in this clinical trial [26, 27]. The investigated populations 
consisted of Indian adult patients and Thai adult patients 
and volunteers, administered with 400  mg of MQ once 
per day over three consecutive days. MQ disposition was 
described by a two compartment model with linear elimi-
nation in both analyses. A first-order and a single transit 
compartment models in Julien et al. [26] and Reuter et al. 
[27], respectively, characterized the absorption phase. 
The two models were implemented in  NONMEM®, fix-
ing simulated individuals’ body weight to the correspond-
ing median population value. Administered MQ doses 
were 110 mg and 400 mg over three consecutive days for 
children and adults, respectively. MQ drug exposure was 
quantified by computing median and  PI95% AUC over the 
whole study period (AUC 0–day63) by NONMEM integra-
tion for all the simulated population/model.
Mefloquine pharmacokinetic–pharmacodynamic analysis
This exploratory analysis was carried out on MQ data 
collected from all children participating in the trial with 
complete dosing history information that did not drop 
out in the early days of the study. Model predicted MQ 
cumulative AUC (AUC 0–dayx) on study days 7, 28, 42, 
and 63 were calculated by concentration integration in 
 NONMEM®. The relationship between recrudescence 
of infection (response variable, coded as 0/1) and model 
predicted AUC 0–dayx (independent variable) on study 
days 7, 28, 42, and 63 was inspected by means of logistic 
regression using STATA (StataCorp. 2013. Stata Statisti-
cal Software: Release 13. College Station, TX: StataCorp 
LP). The independent variable was log-transformed 
(using base 2) and cantered on its median value. The level 
of significance was set at 0.05.
Results
Of the 472 children enrolled in the trial and randomized 
in the ASMQ arm, 21 were removed according to the 
exclusion criteria of the pharmacokinetic analysis. MQ 
and AS/DHA pharmacokinetic model development was 
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carried out on 48 patients and MQ model validation on 
378 patients, after removal of subjects with unreliable 
data. The characteristics of the patients used in the MQ 
and AS/DHA model-building, as well as the final MQ 
model validation and MQ pharmacokinetic–pharmaco-
dynamic analysis datasets, are listed in Table 1.
Population pharmacokinetic analysis
A total of 216 MQ, 117 AS and 134 DHA (including 
BQL) concentrations were available for the 48 Kenyan 
patients selected for the pharmacokinetic model devel-
opment. Of note, none of the MQ concentrations were 
quantified as a BQL, while 71% and 57% of AS and DHA 
samples were BQL data. Median (range) treatment dura-
tion per study subject was 3  days (1–3) and the num-
ber of available non-BQL samples was 5 (1–7) for MQ, 
1 (1–2) for AS and 2 (1–3) for DHA. MQ concentra-
tions ranged between 0.17  ng/mL and 6552.51  ng/mL, 
AS (> BQL) between 2.1 and 8469.8  ng/mL and DHA 
(> BQL) between 2.9 and 2400.9 ng/mL.
Artesunate and dihydroartemisinin
Structural and statistical model
As previously described, a two-compartment model 
was used to simultaneously fit AS and DHA data with 
first-order absorption, drug exclusive elimination via irre-
versible conversion to DHA and first-order elimination of 
metabolite. Initially, BSV was assigned only on CL and 
a mixed error model was assumed for the intra-patient 
variability of both drug and metabolite. Model stability 
was achieved by integrating a correlation between AS 
and DHA concentration measurements (ΔOFV = − 25, 
p < 0.001). BSV on  VC did not improve data descrip-
tion (ΔOFV = 0, p > 0.05) whilst assignment of BSV to 
 CLM (ΔOFV = − 7.3, p < 0.01) and to  VM (ΔOFV = − 8.0, 
p < 0.01) yielded a better fit of the data. Inclusion of rela-
tive F1 (fixed to 100% with estimated BSV) explained 
all the BSV on AS and DHA clearance and significant 
decreased the OFV (ΔOFV = − 17.7, p < 0.01). The esti-
mates and variability (CV%) of the pharmacokinetic 
parameters obtained by the base population model were 
a relative F1 of 100% (67%), a CL of 180 L/h, a  VC of 166 
L, a  CLM of 12.5 L/h and a  VM of 13.8 L (57%).
Covariate analysis
Age, sex and BIL as well as the hepatic liver tests ALT 
and AST had a significant impact on F1 (ΔOFV < − 9.6, 
p < 0.01). Because of poor effect estimation (relative 
standard error, RSE = 155%), BIL was not kept for further 
covariate analyses. Sensitivity analyses revealed that the 
Table 1 Characteristics of  the  children enrolled in  the  trial for  mefloquine and  artesunate/dihydroartemisinin model 
development, mefloquine model validation and pharmacokinetic-pharmacodynamic analysis
AST, aspartate aminotransferase; ALT, alanine aminotransferase
Baseline characteristic Model-building dataset (n = 48) MQ validation dataset (n = 378) MQ pharmacokinetic–
pharmacodynamic analysis 
dataset (n = 451)
Value % or range Value % or range Value % or range
Demographic characteristics
 Sex (male/female) (no.) 19/29 40/60 183/195 48/52 219/232 49/51
 Median age (year) 2.6 0.6–5.0 2.3 0.5–5.0 2.4 0.5–5.0
 Median body weight (kg) 12 7–17 11 5–18 11 5–19
 Median height/length (cm) 89 66–114 85 62–114 86 60–114
Physiological characteristics
 Total bilirubin (μmol/L) 10 1–77 10 0.4–74 17 0.5–163
 Serum creatinine (μmol/L) 42 3–119 36 2–86 40 3–120
 Haematocrit (%) 31 17–49 30 16–59 30 17–62
 Haemoglobin (g/dL) 10 5–15 9 5–18 9 5–19
 AST (IU) 39 5–302 34 7–576 39 5–680
 ALT (IU) 19 7–449 16 4–378 18 3–814
Baseline parasite counts (no/μL)
 Median at day 0 58,131 3322–190,896 – – – –
 Median at day 1 280 0–13,816 – – – –
 Median at day 2 0 0–100 – – – –
Co‑administered drugs
 CYP3A4 inducers (at least for one drug 
measurement/never) (no.)
7/41 15/85 – – – –
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effect of ALT and AST on F1 were purely due to a single 
patient having the highest values for both hepatic enzyme 
tests. Whether this finding was a true or an incidental 
effect could not be validated and these covariates were 
thus not retained in the model. F1 was found to increase 
with the parasite counts (ΔOFV = − 13.2, p < 0.01), and to 
be higher at day 0 compared to days 1 and 2 of treatment 
(ΔOFV = − 13.7, p < 0.01). As shown in Table  1, base-
line parasite counts were extremely high before start-
ing the anti-malarial treatment and dropped to 0 before 
administration of the third ASMQ, a consequence of the 
important and immediate AS effect. Differences in F1 at 
day 0 related to parasite counts were investigated but did 
not improve the fit with respect to the model including 
only the treatment day or the parasite counts as covariate 
(ΔOFV < 3.8, p > 0.05). Because of the correlation between 
the two factors and the absence of fit improvement by 
combining the parasite information and the treatment 
day, only the latter was kept in the model. BW allometric 
scaling on  CLM and  VM markedly decreased the objec-
tive function (AIC difference of − 22 with respect to the 
basic structural model). Maturation on CLM was ade-
quately described using Eq. 3 and improved the model fit 
(ΔOFV = − 18.9, p < 0.01).  VM was significantly impacted 
by sex (ΔOFV = − 8.8, p < 0.01). Complete multivariate 
analyses allowed for the effect of sex on  VM and F1 to be 
discarded, as well as that of maturation on DHA clear-
ance. These results show that F1 is reduced by 68% upon 
doubling child age with respect to the population median 
(2.6 years), and is 29% higher in the first day of therapy 
than in the subsequent treatment days. The effect of BW 
on  CLM and  VM was also retained.
Model evaluation and assessment
The final model parameter estimates, together with 
their bootstrap estimations, are shown in Table  2 and 
the goodness-of-fit plots in Additional file 1. Model pre-
dicted secondary parameters are presented in Table  4. 
Shrinkage was lower than 30% for BSV and 10% for resid-
ual variabilities. The model was considered reliable since 
the parameter estimates were within the bootstrap  CI95% 
and differed less than 15% from their bootstrap estima-
tions. Prediction corrected VPCs shown in fig. 1 evidence 
model misspecification. However, the model was judged 
acceptable because of the paucity of available AS/DHA 
data.
Table 2 Final population parameter estimates of  artesunate and  dihydroartemisinin with  their bootstrap evaluations 
in 2000 replicates
F1, AS relative bioavailability; CL, AS clearance;  VC, AS central volume of distribution;  Ka, first-order absorption rate constant;  CLM, DHA clearance;  VM, DHA volume of 
distribution; σprop, exponential residual error; σadd, additive residual error;  corrprop, correlation between the proportional error components; θage F1, age effect on F1 
expressed as (1 + θage F1(AGE-MAGE)/MAGE) with MAGE = 2.6 years; median AGE value in the study population; θday F1, day effect on F1 expressed as (1 + θday F1Q1) 
with Q1 = 0 for the first treatment day; 1 for subsequent therapy days
a Relative standard error (RSE) of the estimate defined as SE estimate/estimate, expressed as a percentage, with SE estimate retrieved directly from the NONMEM 
output file
b Between-subject variability
c 95% confidence interval (CI)
d Pharmacokinetic parameter of a patient of 12.2 kg, the median population body weight (MBW). DHA individual clearance, and volume of distribution are obtained 
by the equations:  CLM,ind = CLM*(BW/MBW)0.75 and  VM,ind = VM*BW/MBW, respectively, with BW patient’s body weight
Population pharmacokinetics analysis Bootstrap evaluation
Parameter Estimate RSE (%)a BSV (%)b RSE (%)a Estimate CI95% 
c BSV (%)b CI95% 
c
F1 (%) 100 fixed 56 16 100 fixed 53 29 to 70
θday F1 − 0.29 54 − 0.33 − 0.57 to 0.05
θage F1 − 0.68 19 − 0.68 − 0.91 to − 0.31
CL (L/h) 146 20 139 91 to 202
VC (L) 139 23 131 78 to 199
Ka  (h
−1) 3.2 fixed 3.2 fixed
CLM 
d (L/h) 11 15 11 8 to 15
VM
d (L) 11 20 60 29 10 7 to 15 49 16 to 75
σprop,AS (CV%) 79 8 78 65 to 92
σprop,DHA (CV%) 60 9 60 48 to 69
Corrprop (%) 44 36 43 40 to 64
σadd,AS (nmol/mL) 0.0023 3 0.0023 0.0022 to 0.0025
σadd,DHA (nmol/mL) 0.0042 13 0.0041 0.0035 to 0.0049
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Mefloquine
Structural and statistical model
A two-compartment model with first-order absorption 
and elimination described MQ data better than a one-
compartment model (ΔOFV = − 64, p < 0.001). No addi-
tional benefit was observed using three compartments 
(ΔOFV = −  0.9, p > 0.05). BSV on  VC (ΔOFV = − 22, 
p < 0.001) in addition to CL yielded a better fit of the data, 
which was further enhanced by inclusion of BSV on  Ka 
(ΔOFV = − 19, p < 0.001). No improvement of the model 
fit was observed associating BSV on Q or  VP (ΔOFV = 0, 
p > 0.05). The inclusion of MQ F1 fixed to 100% with an 
estimated BSV significantly decreased the OFV whilst 
explaining all the BSV associated to  VC (ΔOFV = −  9.4, 
p < 0.01). Finally, a proportional model was retained to 
describe the intra-patient variability. The estimates and 
variability (CV  %) of the pharmacokinetic parameters 
obtained by the base population model were an F1 of 
100% (39%), a CL of 0.48 L/h (40%), a  VC of 88 L, a Q of 
0.41 L/h, a  VP of 69 L, and a  Ka of 0.15 h−1 (87%).
Covariate analysis
The univariate analyses showed no association between 
the covariates tested and MQ bioavailability, clearances 
and volumes of distribution (ΔOFV ≥ − 3.2, p > 0.05; 
AIC difference of 2 points with respect to the structural 
model for BW on all the PK parameters). However, the 
sensitivity analysis performed while removing the patient 
with extremely low concentrations after the second and 
third ASMQ dose revealed that this outlier masked the 
real impact of BW on clearances and volumes of dis-
tribution and of age on F1 (AIC difference of − 5 and 
ΔOFV = − 5.4, p < 0.05, respectively), without inducing 
any modification in the MQ basic model. Sex and age 
were found to significantly influence  Ka (ΔOFV ≤ − 7.0, 
p < 0.05). A decrease of 74% in  Ka was observed while 
doubling the age with respect to the population median 
(2.6  year) and female children had 55% lower  Ka than 
male children. Multivariate analysis showed that age 
accounted for the effect of sex on  Ka and allowed for the 
discarding of the impact of age on F1. Finally, signifi-
cantly different  Ka at day 0 and 1/2 of ASMQ treatment 
were identified due to improvement in patient health fol-
lowing the first intake of AS (ΔOFV = − 39.2, p < 0.001). 
Multivariate and backward deletion step analyses per-
formed using the reduced dataset, obtained by removal 
of the outlying patient, showed that the BW effect on 
clearances and volumes of distribution, as well as age and 
treatment day effect on  Ka, should be retained in the final 
MQ pharmacokinetic model.
Model evaluation and assessment
The final model parameters, together with their boot-
strap estimations, are displayed in Table  3 and the 
Fig. 1 Prediction corrected visual predictive check of the final model of a artesunate and b dihydroartemisinin. Open circles represent prediction 
corrected observed plasma concentration; black solid and dashed lines the median and  PI90% of the observed data; shaded magenta and grey 
surfaces the model predicted 90% confidence interval of the simulated median and  PI90%, respectively; horizontal black lines are the LOQ of AS 
(0.005 nmol/mL) and DHA (0.005 nmol/mL). The lower panels show the fraction of observed (open circles) with the  PI95% of the simulated (shaded 
magenta surface) BQL data
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goodness-of-fit plots presented in Additional file  2. 
Model predicted secondary parameters are shown in 
Table  4. Shrinkage was 28% for residual variability and 
lower than 15% for BSV. The model was considered relia-
ble since the parameters were within the bootstrap  CI95% 
and differed less than 5% from the bootstrap estimations. 
The results of the pcVPC (Fig. 2) support the predictive 
performance of the model. Moreover, the external valida-
tion done using the remaining 538 concentrations from 
378 children enrolled in the trial showed a negligible bias 
of 0%  (CI95% − 2 to 1%) with a precision of 16% at an indi-
vidual level. A small bias of 18%  (CI95% 13–24%) with a 
precision of 81% was calculated for population predic-
tions. Non-significant or small (absolute values ≤ 6%) 
biases were calculated at each study site on an individual 
level (Table  5). Furthermore, the precision of drug pre-
dictions was close to the estimated residual intra-patient 
variability, which strongly supports the predictive perfor-
mance of the model (Table 5).
Comparison between mefloquine exposures in children 
and adult volunteers and patients
Horizontal black line represents the MQ LOQ (2.5  ng/
mL).
Figure  3 compares the model-predicted AUC 0–day63 
for children and adult volunteers and patients. Median 
 (PI95%) AUC 0–day63 of 725  mg/L/h (310–1718) was com-
puted through simulations of the final pharmacokinetic 
Table 3 Final population parameter estimates of mefloquine with their bootstrap evaluations in 2000 replicates
F1, bioavailability; CL, clearance;  VC, central volume of distribution;  Ka, first-order absorption rate constant; Q, intercompartmental clearance;  VP, peripheral volume of 
distribution; σprop, exponential residual error; θAGE Ka, effect of AGE on  Ka expressed as (1 + θAGE Ka (AGE–AGE)/MAGE) with MAGE = 2.6 years; median AGE value in the 
study population
a Relative standard error (RSE) of the estimate defined as SE estimate/estimate, expressed as a percentage, with SE estimate retrieved directly from the NONMEM 
output file
b Between-subject variability
c 95% confidence interval (CI)
d Pharmacokinetic parameter of a patient of 12.2 kg, the median population body weight (MBW). Individual clearance, peripheral clearance and volumes of 
distribution are obtained by the equations:  CLM,ind = CL*(BW/MBW)0.75,  QM,ind = Q*(BW/MBW)0.75,  VC,ind = VC * BW/MBW, and  VP,ind = VP * BW/MBW, respectively, with BW 
patient’s body weight
Population pharmacokinetics analysis Bootstrap evaluation
Parameter Estimate RSE (%)a BSV (%)b RSE (%)a Estimate CI95% 
c BSV (%)b CI95% 
c
F1 1 FIX 28 15 1 FIX 27 18 to 34
CL (L/h)d 0.45 7 39 17 0.45 0.39 to 0.51 38 24 to 51
VC (L)
d 95 7 92 66 to 106
Ka  (h
−1) DAY = 1 0.17 17 91 12 0.16 0.10 to 0.23 87 64 to 110
Ka  (h
−1) DAY > 1 0.40 22 0.38 0.22 to 0.64
θAGE Ka − 0.67 18 − 0.66 − 0.91 to − 0.29
Q (L/h)d 0.35 28 0.35 0.24 to 1.30
VP(L)
d 60 9 61 51 to 82
σprop (CV %) 21 13 20 14 to 26
Table 4 AS, DHA and MQ final model-predicted secondary pharmacokinetic parameters
Cmax, maximum concentration;  tmax, time to achieve  Cmax;  t1/2, terminal half-life; AUC 0–24, day0 and AUC 0–24, day2, area under the curve (area under the curve) after the first 
and third ASMQ intake, respectively; AUC 0–inf, AUC to infinite
a Two patients received only 1 MQ dose and have a  tmax < 50 h with a  Cmax < 1000 ng/mL
Derived parameter [median 
 (PI95%)]
AS DHA MQ
Cmax 0.52 (0.17, 1.43) nmol/mL 3.9 (1.0, 11.4) nmol/mL 2874 (1099–4994) ng/mL
a
tmax (h) 0.52 1.4 (1.0–1.7) 56 (35–62)
a
t1/2 40 min 40 (20–81) min 12 (9–24) day
AUC 0–24, day 0 (ng/L/h) 0.34 (0.12, 0.93) 3.30 (0.88, 9.30) –
AUC 0–24, day 2 (ng/L/h) 0.23 (0.08, 0.64) 2.20 (0.60, 6.30) –
AUC 0–inf (ng/L/h) – – 650 (251–1619)
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model for children weighting 12.2 kg and taking 110 mg 
of MQ once per day over three consecutive days. Adult 
patients had a median  (PI95%) AUC 0–day63 of 1080 mg/L/h 
(599–1911) and 936 mg/L/h (570–1413) calculated using 
the model of Julien et  al. and Reuter et  al. respectively, 
while adult volunteers of 865 mg/L/h (555–1211) under 
the dosage regimen of MQ 400  mg once per day over 
three consecutive days. Median  (PI90%) concentration 
time profiles for adult and children patient are shown in 
Fig. 4.
Mefloquine pharmacokinetic-pharmacodynamic analysis
Treatment failure was reported for 212 (56%) of the chil-
dren enrolled in the study, of these failures, 81% (n = 171) 
were due to new infections and 7% (15) to recrudescence 
during the 63  days of follow-up. In 2% of the enrolled 
individuals PCR information was missing and in 10% it 
was not possible to determine the nature of the treat-
ment failure. Median (range) model-predicted AUC 0–
day7 were estimated to be 281  mg/L/h (70–854  mg/L/h) 
in children with reported treatment success within the 
follow-up period, and 286  mg/L/h (167–378  mg/L/h) 
and 286  mg/L/h (70–579  mg/L/h) for children with or 
without malaria recrudescence, respectively. No signifi-
cant associations were found through logistic regression 
between model-predicted AUC 0–day at day 7, 28, 42 or 63 
and appearance/absence of recrudescence (p > 0.05) (data 
not shown for day > 7).
Discussion
The present analysis describes the pharmacokinetics 
of fixed-dose ASMQ in African children under the age 
of 5 years, with the aim of identifying the source of the 
significant variability in drug exposure and validating 
the recommended weight-for-age dosage regimen. The 
very short half-lives estimated for AS and DHA are in 
good agreement with reported values ranging from 22 
to 72  min for the drug and from 30 to 186  min for the 
metabolite [28, 29]. The calculated  tmax for AS and DHA 
agree with reported peak AS and DHA plasma concen-
trations within the 1st h and 2 h post-dose, also support-
ing the appropriateness of the value chosen for AS  Ka in 
this work [28, 29].
A two-compartment model was used to describe meflo-
quine pharmacokinetics as already shown in previous 
analyses [26, 27]. Drug clearance and central and periph-
eral volumes of distribution were found to be markedly 
lower than the values estimated in adult patients of Afri-
can, Caucasian or Asian origin [26, 27, 30]. However, 
estimated median terminal half-life and mean absorption 
times are comparable to those obtained for adults [26, 
27, 30–32]. In addition, simulations performed using the 
final model in children and previously published pharma-
cokinetic models in adult patients and volunteers show 
that these populations have comparable exposure under 
the specific recommended dosing regimen.
Considerable between-subject variability characterized 
the pharmacokinetics of both anti-malarial drugs. Such 
variability remained largely unexplained by the inclusion 
of the available covariates. Body weight was associated to 
all the MQ and DHA pharmacokinetic parameters. The 
association between this demographic characteristic and 
Fig. 2 Prediction corrected visual predictive check of the final 
model with MQ prediction corrected plasma concentration (open 
circles) and quartiles (black solid and dashed lines) with model‑based 
percentiles 90% confidence interval (shaded magenta and grey 
surfaces for the median and low/high percentiles, respectively). 
Horizontal black line represents the MQ LOQ (2.5 ng/mL)
Table 5 Final model accuracy and precision per study site 
at individual level
MPE, mean prediction error, calculated as: exp(mean(ln(IPRED/DV)))−1; RMSE, 
root mean square error, calculated as exp(sqrt(mean(ln(IPRED/DV))2))−1. 
IPRED and DV represent the individual predicted and observed concentration, 
respectively
Study sites Observations 
(patients)
MPE  (CI95%) (%) RMSE (%)
Tanzania site no 1 24 (18) − 5 (− 9 to − 1) 12
Kenya site no 2 188 (123) 0 (− 2 to 2) 14
Burkina Faso site no 3 158 (110) 0 (− 2 to 2) 13
Burkina Faso site no 4 78 (55) 2 (− 4 to 8) 30
Tanzania site no 5 68 (52) 0 (− 4 to 2) 14
Tanzania site no 6 22 (20) − 4 (− 7 to − 2) 9
Page 11 of 14Guidi et al. Malar J          (2019) 18:139 
Fig. 3 Model predicted AUC 0–day63 for children and adult patients and volunteers obtained by simulating 1000 individuals with the present 
(children), the Julien et al. (adult patients) and Reuter et al. (adult volunteers and patients) models, respectively [26, 27]
Fig. 4 Median and 90% prediction intervals of MQ concentration–time profiles for children and adult patients receiving 110 mg and 400 mg of MQ 
once per day over three consecutive days obtained with this study (children, magenta solid line and shaded surface), the Julien et al. (adult, light 
grey line and shaded surface), and Reuter et al. (adult, dark grey line and shaded surface) models, respectively [26, 27]
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AS and DHA dispositions has already been described [17, 
33]. Reported discrepancies in MQ disposition and elimi-
nation between adult and children may be ascribed to 
differences in patients’ body weight. These results illus-
trate the association between body weight and AS/DHA 
and MQ dispositions after ASMQ FDC administration 
in African children and thus support the recommended 
dose adjustments according to weight-for-age, in order to 
obtain similar exposures in adults and children.
Twenty-one percent of the initial AS relative F1 varia-
bility was explained by age and treatment day. It is worth 
realizing that F1 is intrinsically connected to AS and 
DHA pharmacokinetic parameters, apparent because of 
ASMQ oral administration. The decrease in F1 observed 
with age implies an increase in drug and metabolite 
eliminations. This effect might thus be related to organ 
maturation in the study population. F1 was significantly 
higher at day 0 than days 1 and 2 of treatment. This is a 
consequence of the rapid and efficacious therapeutic AS 
effect observed already after the first AS dose intake. 
Recently, the relationship between malaria disease and 
AS bioavailability has been described using parasitae-
mia variation [34, 35]. An increase of AS F1, resulting in 
augmented drug exposure, was reported with increasing 
parasite counts. This same trend was found in univari-
ate analysis in the study population but was not retained 
after multivariate combination with treatment day. These 
two covariates are indeed correlated. However, it was not 
possible to identify differences in the first dose F1 due 
to variations in parasite counts in the study population. 
This suggests that the general health improvement and 
not only the disappearance of the parasite after the first 
ASMQ dose affects AS pharmacokinetics.
Age was found to markedly decrease MQ drug absorp-
tion rate. A significantly higher  tmax has been reported 
in healthy fasting volunteers taking an MQ dose com-
pared to those having a high-fat breakfast (36 vs. 17 h), 
meaning that food would increase MQ  Ka [36]. This is 
consistent with the hypothesis that the younger children 
in the African paediatric population investigated were 
breastfed and thus received a more appropriate amount 
of food compared to the older ones. Under this hypoth-
esis, and according to the results of the previously cited 
study, younger children are expected to have higher MQ 
 Ka than older ones. Of note, the impact of food on MQ 
 Ka remains controversial [37, 38]. Finally, the rapid and 
significant therapeutic AS effect, captured in the analysis 
by treatment day, induced a significant increase in MQ 
absorption rate after the first ASMQ FDC administra-
tion. It is possible that the dramatic decrease of parasite 
load following the first intake of AS improves patient 
state of health resulting in the disappearance of gastro-
intestinal tract disturbances [22]. The PK of the second 
and third MQ doses thus might benefit from the AS 
treatment effect with a favourable modification of drug 
absorption rate.
As already described in studies performed in Tanzania 
and Cambodia, more than half of the African paediat-
ric participants had a residual concentration of at least 
one anti-malarial drug above the limit of quantification 
at baseline (lumefantrine was measured in 64% of the 
patients, sulphadoxine in 11%, amodiaquine/deshethyla-
modiaquine in 16%, pyrimethamine in 2% and quinine in 
6%) [39, 40]. These findings are worrying since they indi-
cate that parasites have been exposed to sub-therapeutic 
concentrations of anti-malarials for some time in a pop-
ulation presenting an elevated risk of developing drug 
resistance [22]. This might contribute to the dangerous 
spread of anti-malarial drug resistance.
The MQ model developed in Kenyan children using 
intensive sampling was applied to data collected from 
children from Burkina Faso, Tanzania and Kenya. Simi-
lar non-significant or small biases and precision per 
study centre were estimated, suggesting comparable drug 
exposure among different populations. The relationships 
between therapeutic response and pharmacokinetics of 
MQ as monotherapy and in combination with AS have 
been previously compared in a Thai population [41]. 
Recrudescence of infection in 24% and 2% of patients was 
reported in cases of MQ administered alone and with 
AS, respectively, indicating that the addition of the arte-
misinin derivative improved the cure rates considerably. 
Furthermore, no significant association could be found 
between MQ pharmacokinetics and treatment response. 
In line with these results, only 3% of the African paediat-
ric population studied presented recrudescence of infec-
tion, which could not be related to MQ exposure within 
the study period. The low number of cases of malaria 
recrudescence might have limited the likelihood of 
detecting such an association.
Conclusions
The study described provides the pharmacokinetic 
parameters for MQ and AS, administered as a FDC of 
AS/MQ, in African children under the age of 5 years with 
acute P. falciparum malaria. The considerable variability 
characterizing the pharmacokinetics of these two anti-
malarial drugs can be partly explained by children’s body 
weight, justifying the current dosing recommendations 
based on weight-for-age considerations, to ensure similar 
exposure in children and adults.
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Additional files
Additional file 1. Artesunate (upper panel) and dihydroartemisinin (lower 
panel) goodness‑of‑fit plots of observed vs. individual and population 
predicted concentrations, and conditional weighted residuals (CWRES) vs. 
population predicted concentrations and time after dose.
Additional file 2. Mefloquine goodness‑of‑fit plots of observed vs. 
individual and population predicted concentrations, and conditional 
weighted residuals (CWRES) vs. population predicted concentrations and 
time after dose.
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